Rankings
▼
Calendar
EOLS FY 2023 Earnings — Evolus, Inc. Revenue & Financial Results | Market Cap Arena
EOLS
Evolus, Inc.
$353M
FY 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$202M
+36.0% YoY
Gross Profit
$141M
69.5% margin
Operating Income
-$49M
-24.4% margin
Net Income
-$62M
-30.5% margin
EPS (Diluted)
$-1.08
Cash Flow
Operating Cash Flow
-$34M
Free Cash Flow
-$36M
Stock-Based Comp.
$16M
Balance Sheet
Total Assets
$189M
Total Liabilities
$210M
Stockholders' Equity
-$21M
Cash & Equivalents
$63M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$202M
$149M
+36.0%
Gross Profit
$141M
$90M
+56.5%
Operating Income
-$49M
-$65M
+24.6%
Net Income
-$62M
-$74M
+17.1%
← Q4 2022
All Quarters
Q1 2023 →